MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Dynavax Technologies Corporation Accounts Payables 2011-2026 | DVAX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.06 M | 5.24 M | 3.21 M | 2.6 M | 3.31 M | 9.28 M | 5.28 M | 4.54 M | 3.8 M | 3.43 M | 1.16 M | 1.9 M | 2.17 M | 2.04 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.28 M | 1.16 M | 4.07 M |
Quarterly Accounts Payables Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.95 M | 2.7 M | 4.33 M | 9.06 M | 7.09 M | 4.56 M | 2.43 M | 5.24 M | 3.12 M | 3.25 M | 7.3 M | 3.21 M | 3.05 M | - | 20.2 M | 2.6 M | 3.6 M | 12.1 M | 3.15 M | 3.31 M | 3.31 M | 3.31 M | 3.31 M | 9.28 M | 9.28 M | 9.28 M | 9.28 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 4.54 M | 4.54 M | 4.54 M | 4.54 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.43 M | 3.43 M | 3.43 M | 3.43 M | 1.16 M | 1.16 M | 1.16 M | 1.16 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 2.17 M | 2.17 M | 2.17 M | 2.17 M | 2.04 M | 2.04 M | 2.04 M | 2.04 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.2 M | 1.16 M | 4.28 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aclaris Therapeutics
ACRS
|
4.69 M | $ 2.88 | -4.26 % | $ 223 M | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.9 | -4.5 % | $ 485 M |  Britain |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
51.7 M | $ 10.81 | -4.21 % | $ 699 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.34 | 15.52 % | $ 1.98 M | USA |
 |
Athersys
ATHX
|
9.16 M | - | 3.77 % | $ 22.4 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
10.1 M | - | -7.31 % | $ 87 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
18.5 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 0.21 | 5.66 % | $ 457 M |  Israel |
 |
CASI Pharmaceuticals
CASI
|
4.79 M | $ 0.86 | 0.86 % | $ 117 M | USA |
 |
Calithera Biosciences
CALA
|
3.65 M | - | -10.95 % | $ 876 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 26.33 | -1.68 % | $ 1.28 B | USA |
 |
BeiGene, Ltd.
BGNE
|
405 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Catalyst Biosciences
CBIO
|
355 K | $ 11.18 | -5.73 % | $ 736 M | USA |
 |
Anika Therapeutics
ANIK
|
9.86 M | $ 9.41 | -2.08 % | $ 138 M | USA |
 |
Certara
CERT
|
3.5 M | $ 8.74 | -0.85 % | $ 1.4 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
72 M | $ 563.06 | -0.86 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Celldex Therapeutics
CLDX
|
3.26 M | $ 27.12 | -0.15 % | $ 1.75 M | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.78 | 6.92 % | $ 17.5 M | USA |
 |
Cellectar Biosciences
CLRB
|
5.62 M | $ 3.41 | 15.59 % | $ 41.7 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.09 M | - | - | $ 169 M | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |